Superior Planning, LLC’s Arcutis Biotherapeutics ARQT Stock Holding History

Superior Planning, LLC’s Portfolio ARQT Stock Details ARQT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$211	Buy	+8	New	+$209	﹤0.01%	2024

Other funds holding ARQT

State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return

UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return

Franklin Resources San Mateo, California $474B AUM 32.39% 1-Year Est. Return

American Century Companies Kansas City, Missouri $229B AUM 33.35% 1-Year Est. Return

GW&K Investment Management Boston, Massachusetts $11.8B AUM 29.45% 1-Year Est. Return

Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $71.4B AUM 33.43% 1-Year Est. Return

Candriam SCA Strassen, Luxembourg, Luxembourg $22.5B AUM 50.38% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $6.57B AUM 14.15% 1-Year Est. Return

Superior Planning, LLC's ARQT Position: Q3 2026 in Review

Superior Planning, LLC opened a new position in Arcutis Biotherapeutics (ARQT) in Q3 2026: 8 shares worth $211. The stake represents ﹤0.01% of the portfolio and ranks #2024 among its holdings.

173 funds tracked by Wall St. Rank hold ARQT as of Q3 2026.

Superior Planning, LLC held 8 shares of Arcutis Biotherapeutics worth $211 as of Q3 2026.
Arcutis Biotherapeutics was a new Superior Planning, LLC position in Q3 2026.
Arcutis Biotherapeutics made up ﹤0.01% of Superior Planning, LLC's portfolio in Q3 2026, its #2024 holding.
173 funds tracked by Wall St. Rank held Arcutis Biotherapeutics as of Q3 2026.

Based on Superior Planning, LLC's 13F filing for Q3 2026, filed 12 Nov 2026.